Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Regeneron Pharmaceuticals (NQ: REGN ) 1,199.12 +11.46 (+0.96%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Regeneron Pharmaceuticals < Previous 1 2 3 4 5 6 Next > Regeneron Provides Update on Biologics License Application for Linvoseltamab August 20, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast August 07, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron Reports Second Quarter 2024 Financial and Operating Results August 01, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation July 31, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire CPI Data Sparks Rally in Biotech Stocks July 15, 2024 Following lower-than-expected inflation data on Thursday, The biotech sector broke out above resistance, closing the week up 6%, far outperforming the market. Via MarketBeat Topics ETFs Economy Exposures Interest Rates Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD July 03, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma June 28, 2024 Recommendation based on data from the Phase 1 and pivotal Phase 2 trials demonstrating robust and durable response rates in both relapsed/refractory follicular lymphoma and diffuse large B-cell... From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024 June 27, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine June 26, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma June 16, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) June 11, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD May 31, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation May 31, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO May 23, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine May 20, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Bragar Eagel & Squire, P.C. Is Investigating Zymeworks, Regeneron, Jabil, and DoubleVerify and Encourages Investors to Contact the Firm May 19, 2024 From Bragar Eagel & Squire Via GlobeNewswire More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024 May 17, 2024 Grace Sun, 16, receives $75,000 Top Award for a new kind of organic electrochemical transistor at the world’s largest pre-college science, technology, engineering and math (STEM) competition. From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN) May 16, 2024 From Kirby McInerney LLP Via Business Wire Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) May 13, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Will the Biotech Sector Shift From Lagger to Leader? May 10, 2024 The biotech sector has experienced a significant rally after bouncing off uptrend support and is now consolidating near major SMAs. Via MarketBeat Topics ETFs Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks May 08, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron Announces Investor Conference Presentations May 06, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron Reports First Quarter 2024 Financial and Operating Results May 02, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases April 29, 2024 Long-term data and subgroup analyses from pivotal EYLEA HD clinical program continue to demonstrate durable efficacy and consistent safety in patients with wet age-related macular degeneration and... From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases April 25, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO April 24, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT) April 22, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN) April 18, 2024 From Kirby McInerney LLP Via GlobeNewswire REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Regeneron Stockholders and Encourages Investors to Contact the Firm April 17, 2024 From Bragar Eagel & Squire Via GlobeNewswire The Law Offices of Frank R. Cruz Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors April 17, 2024 From Law Offices of Frank R. Cruz Via Business Wire < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.